Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 [zotarolimus] eluting driver coronary stent in de novo native coronary artery lesions.

Trial Profile

Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 [zotarolimus] eluting driver coronary stent in de novo native coronary artery lesions.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2016

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR-II
  • Most Recent Events

    • 02 Apr 2016 Last checked against clinicaltrials.gov record.
    • 08 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2010 Planned end date changed from 1 May 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top